Michael Andrew Chambers - 10 Aug 2023 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role
Director
Signature
/s/ Ryan Brown, as Attorney-in-Fact for Michael Chambers
Issuer symbol
SRPT
Transactions as of
10 Aug 2023
Net transactions value
+$3,701,067
Form type
4
Filing time
11 Aug 2023, 07:40:04 UTC
Previous filing
08 Mar 2023
Next filing
14 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRPT Common Stock Purchase $230,902 +2,206 +1.2% $104.67 180,670 10 Aug 2023 By Revocable Trust F1
transaction SRPT Common Stock Purchase $115,537 +1,091 +0.6% $105.90 181,761 10 Aug 2023 By Revocable Trust F2
transaction SRPT Common Stock Purchase $3,354,628 +31,570 +17% $106.26 213,331 10 Aug 2023 By Revocable Trust F3
holding SRPT Common Stock 6,431 10 Aug 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $103.99 to $104.98, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $105 to $106, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $106.01 to $106.83, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.